CompletedNCT00135837Updated Jun 21, 2006

Photodynamic Therapy in Occult-Only Lesions (POOL)

A Phase 4 interventional study of Verteporfin for injection in Age-Related Macular Degeneration, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2006-06-21.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Phase: Phase 4
Study type: Interventional
Enrollment: 202
Allocation: Non-randomized
Ages: 50 Years and older
Sex: All

Study summary

Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.

Conditions studied

Age-Related Macular Degeneration

Browse trials for

Keywords

Age related Macula Degeneration,
AMD,
choroidal neovascularisation (CNV),
occult CNV lesion,
verteporfin for injection,
photodynamic therapy (PDT)

In context

Macular Degeneration

1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.

This study's enrollment of 202 is above the median of 51 across 985 interventional studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 50 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

50 years or older
Must see better or equal to 34 letters (visual acuity)
Choroidal neovascularization (CNV) lesion must be occult only

Exclusion criteria

Exclusion Criteria:

Evidence of classic CNV in the lesion
Prior treatment of disease in study eye
Have a history of moderate to severe hepatic impairment

Other protocol-defined exclusion criteria may apply.

Study design

Phase: Phase 4
Primary purpose: Treatment
Allocation: Non-randomized
Intervention model: Single group
Masking: None (open label)
Enrollment: 202 participants

Interventions

DrugVerteporfin for injection

What researchers measure

Primary outcomes

visual acuity measurements, baseline, 12 months

Secondary outcomes

visual acuity measurements, fundus photographs and fluorescein angiography at baseline, 12 months; ophthalmic examinations, adverse events, vital signs, concomitant medications, 12 months

Study locations

1 site

Novartis
Basel, Switzerland

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jun 21, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00135837
Lead sponsor: Novartis
Collaborators: QLT Inc.
First posted: Aug 26, 2005
Start date: Jun 2003
Last update: Jun 21, 2006

Study contacts

Novartis Customer Information

study chair · Novartis

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Macular Degeneration→

Other studies from this sponsor

Novartis

Start the discussion